接受抗雄激素治疗的前列腺癌患者使用糖皮质激素与主要不良心血管事件之间的关联：一项回顾性队列研究。
Associations between glucocorticoid use and major adverse cardiovascular events in patients with prostate cancer receiving antiandrogen: a retrospective cohort study.
发表日期：2024 Sep 10
作者：
Jeffrey Shi Kai Chan, Yan Hiu Athena Lee, Chi Ho Leung, David Ka Wai Leung, Edward Christopher Dee, Kenrick Ng, Gary Tse, Chi Fai Ng
来源：
PROSTATE CANCER AND PROSTATIC DISEASES
摘要：
泼尼松龙/泼尼松与阿比特龙联合用药可能解释阿比特龙相关的心血管风险增加。我们探讨了这一假设以及糖皮质激素与心血管风险的关联。接受雄激素剥夺治疗和恩杂鲁胺或阿比特龙每日 5mg (ABI P5) 或 10mg (ABI P10) 每日总泼尼松龙/泼尼松的前列腺癌患者随访主要不良心血管事件事件 (MACE)。我们分析了 933 名患者。 ABI P10（而非恩杂鲁胺）发生 MACE 的风险高于 ABI P5。恩杂鲁胺/阿比特龙开始治疗前的累积糖皮质激素剂量与 MACE 相关。泼尼松龙/泼尼松与阿比特龙合用可能导致与阿比特龙相关的心血管风险增加。普遍累积糖皮质激素剂量与心血管风险相关。© 2024。作者。
Prednisolone/prednisone coadministration with abiraterone may explain abiraterone-related increase in cardiovascular risk. We explored this postulation and glucocorticoid's association with cardiovascular risk.Patients with prostate cancer on androgen deprivation therapy and enzalutamide, or abiraterone with 5 mg (ABI + P5) or 10 mg (ABI + P10) daily total prednisolone/prednisone were followed up for major adverse cardiovascular events (MACE).We analyzed 933 patients. ABI + P10, but not enzalutamide, had higher risk of MACE than ABI + P5. Cumulative glucocorticoid dose before enzalutamide/abiraterone initiation was associated with MACE.Prednisolone/prednisone coadministration with abiraterone likely contributed to abiraterone-related increased cardiovascular risk. Prevalent cumulative glucocorticoid dose was associated with cardiovascular risk.© 2024. The Author(s).